Table 4. Relation between Arg462Gln and Asp541Glu genotypes and clinical stage of prostate cancer.
|
No. of subjects (%) |
||||
|---|---|---|---|---|
| Genotype | Localised | Metastatic | OR (95%CI) | P-value |
| Arg462Gln | 51 (68.%) | |||
| Arg/Arg | 24 (32.0%) | 17 (70.8%) | 1.0 (Ref.) | |
| Arg/Gln | 0 (0.0%) | 7 (29.2%)) | 0.88 (0.50–1.53) | 0.79 |
| Gln/Gln | 0 (0.0%) | |||
| Asp541Glu | ||||
| Glu/Glu | 39 (52.0%) | 12 (50.0%) | 1.0 (Ref.) | |
| Glu/Asp | 25 (33.3%) | 5 (20.8%) | 0. 65 (0.37–1.13) | 0.46 |
| Asp/Asp | 11 (14.7%) | 7 (29.2%) | 2.07 (1.19–3.61)) | 0.21 |
| Glu/Glu+Glu/Asp | 64 (85.3%) | 17 (70.8%) | 1.0 (Ref.) | |
| Asp/Asp | 11 (14.7%) | 7 (29.2%) | 2.40 (1.37–4.18) | 0.11 |
Two cases were excluded due to lack of staging information.